Shots:
- Polpharma Biologics has signed a licensing agreement with Brazil-based Libbs Farmacêutica for an autoimmune biosimilar
- Under this strategic partnership, Polpharma Biologics is fully responsible for the development and manufacturing of the product
- Libbs will exclusively handle the product’s commercialization, marketing, and distribution in the Brazilian market
Ref: Polpharma Biologics | Image: Polpharma Biologics | Press Release
Related News:- Polpharma Biologics Launches Ranivisio PFS (Biosimilar, Lucentis) in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
